These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1803779)

  • 1. [A comparative study of the immunological indices in guinea pigs administered an inactivated Marburg virus].
    Ignat'ev GM; Agafonov AP; Strel'tsova MA; Kuz'min VA; Maĭnagasheva GI; Spirin GV; Chernyĭ NB
    Vopr Virusol; 1991; 36(5):421-3. PubMed ID: 1803779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The immunity indices of animals immunized with the inactivated Marburg virus after infection with homologous virus].
    Ignat'ev GM; Strel'tsova MA; Agafonov AP; Zhukova NA; Kashentseva EA; Vorob'eva MS
    Vopr Virusol; 1994; 39(1):13-7. PubMed ID: 8160440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivated Marburg virus elicits a nonprotective immune response in Rhesus monkeys.
    Ignatyev GM; Agafonov AP; Streltsova MA; Kashentseva EA
    J Biotechnol; 1996 Jan; 44(1-3):111-8. PubMed ID: 8717394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses.
    Swenson DL; Warfield KL; Larsen T; Alves DA; Coberley SS; Bavari S
    Expert Rev Vaccines; 2008 May; 7(4):417-29. PubMed ID: 18444889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effectiveness of virus-specific proteins in immunogenesis during experimental Marburg fever].
    Donchenko VV; Lebedev VN; Markin VA; Firsova IV
    Vopr Virusol; 1996; 41(5):216-8. PubMed ID: 8967067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection.
    Warfield KL; Swenson DL; Negley DL; Schmaljohn AL; Aman MJ; Bavari S
    Vaccine; 2004 Sep; 22(25-26):3495-502. PubMed ID: 15308377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A bioluminescent imaging mouse model for Marburg virus based on a pseudovirus system.
    Zhang L; Li Q; Liu Q; Huang W; Nie J; Wang Y
    Hum Vaccin Immunother; 2017 Aug; 13(8):1811-1817. PubMed ID: 28481728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deadly Marburg virus: scientists race to test vaccines in outbreak.
    Callaway E
    Nature; 2024 Oct; 634(8033):278. PubMed ID: 39354138
    [No Abstract]   [Full Text] [Related]  

  • 9. A single shot against Ebola and Marburg virus.
    Baize S
    Nat Med; 2005 Jul; 11(7):720-1. PubMed ID: 16015361
    [No Abstract]   [Full Text] [Related]  

  • 10. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates.
    Hevey M; Negley D; Pushko P; Smith J; Schmaljohn A
    Virology; 1998 Nov; 251(1):28-37. PubMed ID: 9813200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Good news for Marburg virus workers.
    Becker S
    Lancet; 2006 Apr; 367(9520):1373-4. PubMed ID: 16650630
    [No Abstract]   [Full Text] [Related]  

  • 12. Complex adenovirus-vectored vaccine protects guinea pigs from three strains of Marburg virus challenges.
    Wang D; Hevey M; Juompan LY; Trubey CM; Raja NU; Deitz SB; Woraratanadharm J; Luo M; Yu H; Swain BM; Moore KM; Dong JY
    Virology; 2006 Sep; 353(2):324-32. PubMed ID: 16820184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Design of equine serum-based Marburg virus immunoglobulin].
    Borisevich IV; Potryvaeva NV; Mel'nikov SA; Evseev AA; Krasnianskiĭ VP; Maksimov VA
    Vopr Virusol; 2008; 53(1):39-41. PubMed ID: 18318136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The immunogenic properties of Marburg virus proteins].
    Agafonov AP; Ignat'ev GM; Kuz'min VA; Akimenko ZL; Kosareva TV; Kashentseva EA
    Vopr Virusol; 1992; 37(1):58-61. PubMed ID: 1413715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanisms of protective immune response in models of Marburg fever in monkeys].
    Ignat'ev GM; Strel'tsova MA; Agafonov AP; Kashentseva EA
    Vopr Virusol; 1995; 40(3):109-13. PubMed ID: 7676670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A trial to produce an inactivated Lassa fever vaccine].
    Krasnianskiĭ VP; Potryvaeva NV; Borisevich IV; Gradoboev VN; Pashanina TP; Pshenichnov VA
    Vopr Virusol; 1993; 38(6):276-9. PubMed ID: 8303891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postexposure treatment of Marburg virus infection.
    Geisbert TW; Hensley LE; Geisbert JB; Leung A; Johnson JC; Grolla A; Feldmann H
    Emerg Infect Dis; 2010 Jul; 16(7):1119-22. PubMed ID: 20587184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De novo syntheses of Marburg virus antigens from adenovirus vectors induce potent humoral and cellular immune responses.
    Wang D; Schmaljohn AL; Raja NU; Trubey CM; Juompan LY; Luo M; Deitz SB; Yu H; Woraratanadharm J; Holman DH; Moore KM; Swain BM; Pratt WD; Dong JY
    Vaccine; 2006 Apr; 24(15):2975-86. PubMed ID: 16530297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [An evaluation of the possibility of obtaining an inactivated vaccine against Lassa fever].
    Krasnianskiĭ VP; Potryvaeva NV; Borisevich IV; Gradoboev VN; Pashanina TP; Pshenichnov VA
    Zh Mikrobiol Epidemiol Immunobiol; 1994; (6):74-5. PubMed ID: 7879553
    [No Abstract]   [Full Text] [Related]  

  • 20. Marburg vaccine shows promise: offers postexposure protection in monkeys.
    Hampton T
    JAMA; 2006 May; 295(20):2346. PubMed ID: 16720816
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.